Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the stock.

Ampio Pharmaceuticals Trading Down 12.9 %

Ampio Pharmaceuticals stock opened at $0.62 on Friday. The stock has a market cap of $706,800.00, a price-to-earnings ratio of -0.06 and a beta of 1.95. The company’s 50-day moving average price is $1.47 and its two-hundred day moving average price is $2.09. Ampio Pharmaceuticals has a 52 week low of $0.62 and a 52 week high of $8.30.

Hedge Funds Weigh In On Ampio Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Bank of Montreal Can bought a new position in shares of Ampio Pharmaceuticals during the 1st quarter valued at about $168,000. BlackRock Inc. boosted its position in shares of Ampio Pharmaceuticals by 0.4% during the 1st quarter. BlackRock Inc. now owns 13,996,074 shares of the company’s stock valued at $6,578,000 after purchasing an additional 61,269 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Ampio Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 9,307,338 shares of the company’s stock valued at $4,375,000 after purchasing an additional 77,822 shares in the last quarter. State Street Corp boosted its position in shares of Ampio Pharmaceuticals by 2.0% during the 1st quarter. State Street Corp now owns 3,430,770 shares of the company’s stock valued at $1,612,000 after purchasing an additional 66,375 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Ampio Pharmaceuticals during the 2nd quarter valued at about $72,000. Institutional investors and hedge funds own 5.73% of the company’s stock.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.